These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9294123)

  • 21. Functional characterization of five V2 vasopressin receptor gene mutations.
    Wenkert D; Schoneberg T; Merendino JJ; Rodriguez Pena MS; Vinitsky R; Goldsmith PK; Wess J; Spiegel AM
    Mol Cell Endocrinol; 1996 Nov; 124(1-2):43-50. PubMed ID: 9027323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterization of novel loss-of-function mutations in the vasopressin type 2 receptor gene causing nephrogenic diabetes insipidus.
    Böselt I; Tramma D; Kalamitsou S; Niemeyer T; Nykänen P; Gräf KJ; Krude H; Marenzi KS; Di Candia S; Schöneberg T; Schulz A
    Nephrol Dial Transplant; 2012 Apr; 27(4):1521-8. PubMed ID: 21917732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agonist and antagonist-dependent internalization of the human vasopressin V2 receptor.
    Pfeiffer R; Kirsch J; Fahrenholz F
    Exp Cell Res; 1998 Oct; 244(1):327-39. PubMed ID: 9770376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression studies of two vasopressin V2 receptor gene mutations, R202C and 804insG, in nephrogenic diabetes insipidus.
    Tsukaguchi H; Matsubara H; Inada M
    Kidney Int; 1995 Aug; 48(2):554-62. PubMed ID: 7564126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A fully active nonglycosylated V2 vasopressin receptor.
    Innamorati G; Sadeghi H; Birnbaumer M
    Mol Pharmacol; 1996 Sep; 50(3):467-73. PubMed ID: 8794883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Chinese hamster ovary cell line for recombinant adenovirus-mediated gene expression.
    Condon RG; Schaefer EJ; Santoro M; Longley R; Tsao YS; Zurawski SM; Liu Z
    Biotechnol Prog; 2003; 19(1):137-43. PubMed ID: 12573016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrogenic diabetes insipidus.
    Bichet DG
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):96-104. PubMed ID: 16580609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of multiple pathophysiological phenotypes of klotho (kl/kl) mice by adenovirus-mediated expression of the klotho gene.
    Shiraki-Iida T; Iida A; Nabeshima Y; Anazawa H; Nishikawa S; Noda M; Kuro-o M; Nabeshima Y
    J Gene Med; 2000; 2(4):233-42. PubMed ID: 10953914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene transfer by adenovirus-mimetic peptides in the presence of a cationic lipid and/or adenovirus. Analysis of the contribution of the viral and nonviral components.
    Moritz S; Colin M; Keller M; Klonjkowski B; Capeau J; Coutelle C; Chroboczek J; Brahimi-Horn MC
    Arch Virol; 2003 Jan; 148(1):1-18. PubMed ID: 12536292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
    Gimpl G; Postina R; Fahrenholz F; Reinheimer T
    Eur J Pharmacol; 2005 Mar; 510(1-2):9-16. PubMed ID: 15740719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
    J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
    Slusarz MJ; Slusarz R; Ciarkowski J
    Biopolymers; 2006 Apr; 81(5):321-38. PubMed ID: 16333859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
    Bernier V; Morello JP; Zarruk A; Debrand N; Salahpour A; Lonergan M; Arthus MF; Laperrière A; Brouard R; Bouvier M; Bichet DG
    J Am Soc Nephrol; 2006 Jan; 17(1):232-43. PubMed ID: 16319185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered regulation of the D(1) dopamine receptor in mutant Chinese hamster ovary cells deficient in cyclic AMP-dependent protein kinase activity.
    Ventura AL; Sibley DR
    J Pharmacol Exp Ther; 2000 May; 293(2):426-34. PubMed ID: 10773012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of receptor-mediated cAMP production: role in the cross-talk between vasopressin V1a and V2 receptor transduction pathways.
    Klingler C; Ancellin N; Barrault MB; Morel A; Corman B
    Biochem J; 1998 Mar; 330 ( Pt 2)(Pt 2):1023-8. PubMed ID: 9480925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The property of a novel v2 receptor mutant in a patient with nephrogenic diabetes insipidus.
    Inaba S; Hatakeyama H; Taniguchi N; Miyamori I
    J Clin Endocrinol Metab; 2001 Jan; 86(1):381-5. PubMed ID: 11232028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular pharmacology of human vasopressin receptors.
    Thibonnier M; Conarty DM; Preston JA; Wilkins PL; Berti-Mattera LN; Mattera R
    Adv Exp Med Biol; 1998; 449():251-76. PubMed ID: 10026814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of thyrotropin-releasing hormone receptors by adenovirus-mediated gene transfer reveals that thyrotropin-releasing hormone desensitization is cell specific.
    Falck-Pedersen E; Heinflink M; Alvira M; Nussenzveig DR; Gershengorn MC
    Mol Pharmacol; 1994 Apr; 45(4):684-9. PubMed ID: 8183247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo.
    Sangkuhl K; Schulz A; Römpler H; Yun J; Wess J; Schöneberg T
    Hum Mol Genet; 2004 May; 13(9):893-903. PubMed ID: 14998935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.